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Posttranslational modification of metazoan nucleo-
cytoplasmic proteins with N-acetylglucosamine
(O-GlcNAc) is essential, dynamic, and inducible and
can compete with protein phosphorylation in signal
transduction. Inhibitors ofO-GlcNAcase, the enzyme
removing O-GlcNAc, are useful tools for studying
the role ofO-GlcNAc in a range of cellular processes.
We report the discovery of nanomolar OGA inhibitors
that are up to 900,000-fold selective over the related
lysosomal hexosaminidases. When applied at nano-
molar concentrations on live cells, these cell-pene-
trant molecules shift the O-GlcNAc equilibrium
toward hyper-O-GlcNAcylation with EC50 values
down to 3 nM and are thus invaluable tools for the
study of O-GlcNAc cell biology.
INTRODUCTION
The O-GlcNAc modification was discovered more than two
decades ago by Torres and Hart (1984). This modification
consists of a single GlcNAc sugar that is dynamically and
reversibly transferred onto/hydrolyzed from serine/threonine
residues on proteins in the nucleocytoplasm (Hart et al., 2007;
Hanover et al., 2010). Similar to protein phosphorylation, the
O-GlcNAc modification has been shown to be involved in
signaling processes and to occupy serine/threonine residues
identical, or adjacent, to known protein phosphorylation sites
(Roquemore et al., 1996; Chou et al., 1992; Zachara and Hart,
2006; Hart et al., 2007). O-GlcNAc transfer is performed by
a single enzyme, the O-GlcNAc transferase (OGT) (Kreppel
et al., 1997; Lubas et al., 1997). The O-GlcNAc modification is
removed by a single enzyme termed O-GlcNAcase (OGA)
(Gao et al., 2001).
A range of approaches has been used to gain insight into the
function of O-GlcNAc and its possible regulation of signaling
pathways, including genetic manipulation (Bowe et al., 2006;
Ngoh et al., 2009) and blocking O-GlcNAc hydrolysis with small
molecules that inhibit hOGA. A number of hOGA inhibitors have
been described and used to demonstrate the involvement of
O-GlcNAc in the insulin response (Akimoto et al., 2007), regula-
tion of Tau phosphorylation (Yuzwa et al., 2008), Akt activation1250 Chemistry & Biology 17, 1250–1255, November 24, 2010 ª2010(Vosseller et al., 2002), and, recently, in regulation of cellular
volume (Nagy et al., 2009). However, many of these inhibitors
possess limited selectivity over the structurally related lysosomal
hexosaminidases A/B (HexA/B) and/or are only active on cells in
the high micromolar range, increasing the risk of off-target
effects, as suggested recently by Macauley et al. (2008), Yuzwa
et al. (2008), and Dorfmueller et al. (2006, 2009).
Here we have attempted to target a conserved hOGA active
site cysteine with suicide inhibitors, based on the GlcNAcstatin
scaffold. These novel compounds are up to 900000-fold selec-
tive over HexA/B, penetrating the OGA active site as revealed
by X-ray crystallography. The compounds penetrate live cells,
inducing hyper-O-GlcNAcylation when used at low nanomolar
concentrations. The new GlcNAcstatins will be useful tools for
studying the role of O-GlcNAc in cellular signaling pathways.
RESULTS AND DISCUSSION
Design of Novel GlcNAcstatin-Based Suicide OGA
Inhibitors
GlcNAcstatins (Figure 1A), a novel family of potent human OGA
inhibitors, have recently been reported to possess 150-fold
selectivity over hHexA/B (Dorfmueller et al., 2006, 2009).
Based on the structural data of GlcNAcstatins in complex with
a bacterial OGA from C. perfringens (CpOGA) (Figure 2A), we
assumed that increased selectivity for hOGA over the HexA/B
could be achieved by extending the size of the N-acyl derivative.
However, similar elaboration of the NAG-thiazoline/PUGNAc
scaffolds reduced inhibition from nanomolar to micromolar
range (Macauley et al., 2005; Stubbs et al., 2006). A structural
comparison of the active site pockets from CpOGA (Dorfmueller
et al., 2009) and hHexA (Lemieux et al., 2006) and hHexB (Mark
et al., 2003) reveals obvious differences in the N-acetyl binding
pocket (Figure 2A). The b-hexosaminidases have a narrower
(difference of approximately 1.4 A˚) and shallower (difference of
approximately 5.0 A˚) pocket than the OGA enzymes (Figure 2A).
Interestingly, a cysteine residue is located at the bottom of the
hOGA active site (Cys215) (Figure 2B). This cysteine is
conserved in metazoan OGAs, and hOGA is potently inhibited
by a thiol-reactive compound (Dong and Hart, 1994).
In an attempt to generate a potent, selective hOGA ‘‘suicide’’
inhibitor, the N-acyl group of GlcNAcstatin D was extended and
modified to contain thiol-reactive groups that could irreversibly
react with the cysteine located in a pocket at the bottom of the
active site. GlcNAcstatin F carries a 3-mercaptopropanamideElsevier Ltd All rights reserved
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Figure 1. GlcNAcstatins and Their Inhibitory
Activities
(A) Chemical structures of GlcNAcstatins C, D,
and F–H.
(B) Lineweaver-Burk analysis of hOGA steady-
state kinetics measured in the presence of
0–40 nM GlcNAcstatin G at pH 7.3. Data were
fitted using the standard equation for competitive
inhibition in the GraFit program (Leatherbarrow,
2001), yielding a Ki of 4.1 nM (Table 1).
(C) Dose-response curve of hHexA/B inhibition
GlcNAcstatins C and F–H. Data were fitted using
the standard IC50 equation in the GraFit program
(Leatherbarrow, 2001).
(D) Characterization of pH optimum of hOGA
catalytic activity (open circles) and GlcNAcstatin
C inhibition (black dots). The catalytic activity
was measured using a McIlvaine buffer system
over a 4.9–8.1 pH range. Data for 1/Ki and kcat/Km
were plotted versus the pH and fitted by nonlinear
regression to the bell-shaped double pKa equation
in the program GraphPad Prism. The pH optimum
for hOGA hydrolytic activity is pH 7.3 (right y-axis),
and the pH optimumGlcNAcstatin C inhibition is at
pH 6.6 (left y-axis).
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mide derivative, both potentially able to react with the hOGA
Cys215. GlcNAcstatin H, a saturated derivative of GlcNAcstatin
G, was synthesized as a control (Figure 1A). The synthesis will be
reported elsewhere.GlcNAcstatins F–H Show Increased hOGA Selectivity
while Retaining Potency
The new GlcNAcstatin derivatives were evaluated in kinetic
studies for their ability to inhibit recombinant hOGA. The
pH optimum of hOGA is 7.3 (Figure 1D), whereas the first
GlcNAcstatin inhibitor reported (GlcNAcstatin C) inhibits with
maximum potency at pH 6.6 (Ki = 2.9 nM) (Figure 1D). At
pH 7.3, GlcNAcstatins F–H show time-independent inhibition in
the 2.6–11.2 nM range (Table 1 and Figures 1A and 1B). To
assess selectivity, inhibition of hHexA/B was also investigated
(Figure 1C). The extension of the N-propionyl side chain of
GlcNAcstatin D with an additional thiol group (GlcNAcstatin F)
increases selectivity for hOGA to 1000-fold (Figure 1C and
Table 1), showing that the elongated N-acyl substitution abol-
ishes the binding of the compound to hHexA/B (Table 1). Strik-
ingly, the more extended GlcNAcstatin G inhibits hHexA/B with
an approximate IC50 of only 7 mM (Figure 1C and Table 1),
thus resulting in a >900,000-fold selectivity for GlcNAcstatin G
toward hOGA, representing the most selective hOGA inhibitor
reported to date.Chemistry & Biology 17, 1250–1255, November 24, 2010 ªThe 3-Mercaptopropanamide Side
Chain of GlcNAcstatin F Efficiently
Occupies the Selectivity Pocket
The molecular basis of the increased
selectivity of the new GlcNAcstatin
derivatives was investigated by X-ray
crystallography using the CpOGA V331Cmutant that perfectly mimics the hOGA active site (Dorfmueller
et al., 2009) (Figure 2B). The CpOGA-V331C GlcNAcstatin
F complex (2.5 A˚ resolution) reveals that the inhibitor-binding
mode is similar to the previously reported GlcNAcstatin C/D
complexes (Dorfmueller et al., 2006, 2009) (Figure 2B). The
3-mercaptopropanamide moiety points straight into the
pocket of the active site, whereas all hydrogen bonds seen in
the GlcNAcstatin C/D complexes are conserved. Interestingly,
the sulfhydryl group of GlcNAcstatin F approaches the active
site cysteine (Cys215 in hOGA, equivalent to Cys331 in the
V331C-CpOGA mutant) to within 3.5 A˚ (Figure 2B), although
the side chain thiol points away from the inhibitor, and no
disulfide bond is formed, in agreement with the absence of
time-dependent inhibition. A structural superposition of the
GlcNAcstatin F-V331C-CpOGA complex onto the structure of
hHexA (Figure 2C) reveals that the shallower N-acetyl binding
pocket in the HexA structure would produce steric clashes
with the 3-mercaptopropanamide moiety, also explaining the
increased selectivity for hOGA of >900,000-fold for the further
elongated penta-2,4-dienamide substituent (GlcNAcstatin G).
GlcNAcstatin G Penetrates HEK293 Cells
No direct evidence has so far been provided for any known
hOGA inhibitor penetrating the cell and inducing cellular hyper-
O-GlcNAcylation by direct inhibition of intracellular hOGA. We
have used a mass-spectrometric approach to measure intracel-
lular GlcNAcstatin G concentrations in HEK293 cells. HEK2932010 Elsevier Ltd All rights reserved 1251
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Figure 2. Binding of GlcNAcstatins to
CpOGA
(A) Comparison of the active-site architecture of
OGA enzymes and hexosaminidases. The active
site of CpOGA in complex with GlcNAcstatin D
(PDB entry 2WB5) (Dorfmueller et al. [2009]) is
shown in a semitransparent surface representa-
tion. GlcNAcstatin D is shown in sticks with green
carbon atoms. hHexA in complex with NAG-thia-
zoline (PDB entry 2GK1) (Lemieux et al. [2006]) is
shown with NAG-thiazoline in sticks with green
carbon atoms. The residues blocking the active
site from this side view (Tyr335 in CpOGA and
Trp392 in hHexA) have been removed in these
images for clarity. Hydrogen bonds between the
ligands and active site residues are indicated by
black dashed lines.
(B) Stereo figure of the crystal structure of GlcNAc-
statin F (sticks with green carbon atoms) in
complex with V331C-CpOGA. Hydrogen bonds
are indicated by black dashed lines. An unbiased
jFo j jFc j, 4calc electron density map calculated
without the model having seen the inhibitor in
refinement is shown at 2.75 s.
(C) Stereo figure of a superimposition of GlcNAc-
statin F onto the hHexA-thiazoline complex. Semi-
transparent surface representation of hHexA in
complex with NAG-thiazoline (green carbon
atoms) (PDB entry: 2GK1) (Lemieux et al. [2006]).
GlcNAcstatin F (magenta carbon atoms) is super-
imposed onto NAG-thiazoline.
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(1 and 10 mM) for 1.5 and 6 hr. An equal number of cultured cells
were lysed, and the intracellular volume was investigated by
UPLC-MS/MS. On the basis of the average cell size (13.1–
15.7 mm) and the number of cultured cells (1.4 3 106 to 2.2 3
106), the maximal cellular volume and, thus, the minimal dilution
factor of the intracellular volume upon the addition of lysis buffer
were calculated (280-fold). Treatment of HEK293 cells with
10 mM GlcNAcstatin G resulted in a minimal inhibitor concentra-
tion of 270 nM after 1.5 hr and 380 nM after 6 hr. Application
of a 1 mM extracellular concentration resulted in a 10-fold lower
intracellular concentration of at least 30 and 40 nM, after 1.5
and 6 hr treatment, respectively. To our knowledge, these1252 Chemistry & Biology 17, 1250–1255, November 24, 2010 ª2010 Elsevier Ltd All rights rdata provide the first direct evidence
that GlcNAcstatins are cell-penetrant
compounds.
GlcNAcstatins Effectively Induce
Cellular Hyper-O-GlcNAcylation
at Low Nanomolar Concentrations
The novel GlcNAcstatin derivatives were
investigated for their activity on endoge-
nous hOGA in a cell-based assay with
HEK293 cells. Cells were exposed for
6 hr to a range of inhibitor concentrations
and investigated for an increase of cellular
O-GlcNAcylation levels by western blot-
ting using an anti-O-GlcNAc antibody
(CTD110.6), followed by the fitting ofdensitometric data to a standard dose-response curve (Fig-
ure 3A), yielding EC50s of 20 nM for both GlcNAcstatins C and
G, and an EC50 of 290 nM for GlcNAcstatin F. Treatment with
concentrations as low as 100 nM of GlcNAcstatin G in the culture
media appears to already induce maximum levels of O-GlcNA-
cylation (Figure 3A). Furthermore, we determined the EC50 of
GlcNAcstatins G and H by O-GlcNAc microscopy assay (Fig-
ure 3B; see Figure S1 available online). Elevated total O-GlcNAc
levels in HEK293 cells were quantified and normalized over
a reference DAPI signal. Dose-response curves of these anal-
yses yielded EC50 values of 3 and 42 nM for GlcNAcstatins G
and H, respectively, in good agreement with the immunoblot-
ting-derived data (Figures 3A and 3B).eserved
Table 1. Inhibition Data and Selectivity of GlcNAcstatins C and F–H, PUGNAc, and Thiamet-G against Lysosomal hHexA/HexB, Human
OGA and CpOGA-WT and V331C-CpOGA Mutant
Ki (mM) Ki (nM) Selectivity Ki (nM) Ki (nM)
hHex A/Ba hOGAb (hHexA/B/hOGA) CpOGA-wild-type V331C-CpOGA
GlcNAcstatin C 0.6 ± 0.1 3.2 ± 0.9 190 0.0046 ± 0.0002c 0.098 ± 0.006c
GlcNAcstatin F 11.0 ± 0.6d 11.2 ± 1.4 1,000 0.0032 ± 0.0002 0.005 ± 0.001
GlcNAcstatin G >3,700d 4.1 ± 0.7 >900,000 0.0078 ± 0.0007 0.019 ± 0.002
GlcNAcstatin H 100 ± 30d 2.6 ± 0.3 35,000 nd nd
PUGNAc 0.036e 50e ns 5.4 ± 0.4 nd
Thiamet-G 750f 21f 35,000 nd nd
nd, not determined; ns, no selectivity for hOGA.
a The Cheng-Prusoff equation (Ki = IC50/(1 + [S]/Km)) was used to convert the IC50 values to an absolute inhibition constant (Ki).
b At physiological pH 7.3.
c From Dorfmueller et al. (2009).
d These values are approximate IC50s, obtained after including an artificial 100% inhibition point at an inhibitor concentration of 1000 M.
e From Macauley et al. (2005).
f From Yuzwa et al. (2008).
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GlcNAcstatin G provide potent and selective chemical biological
dissection tools as an attractive alternative to genetic
approaches for modulating intracellular O-GlcNAc levels in cells
to study the role of O-GlcNAc in signal transduction.
SIGNIFICANCE
Selective inhibition of human O-GlcNAcase is a useful
strategy to study the role of the O-GlcNAc modification in
living cells. Previously reported compounds showed unde-
sirable inhibition of the human lysosomal hexosaminidases,
and there has been no direct evidence of the cell penetration
of these compounds. This work reports derivatives of the
GlcNAcstatin scaffold, showing potent inhibition of human
O-GlcNAcase with up to 900,000-fold weaker inhibition of
the lysosomal hexosaminidases. These are the most selec-
tive human O-GlcNAcase inhibitors known to date and
penetrate live cells to induce cellular hyper-O-GlcNAcylation
levels with EC50s in the low nanomolar range.
EXPERIMENTAL PROCEDURES
Determination of the CpOGA-GlcNAcstatin F Complex Crystal
Structure
Cloning, expression, purification, and crystallization of hOGA and/or CpOGA
have been described previously (Dorfmueller et al., 2009). Diffraction data
for a CpOGA-V331C GlcNAcstatin F complex were collected on BM-14
(ESRF, Grenoble) to 2.4 A˚ (Table 2). Refinement to 2.5 A˚ resolutionwas initiated
from the protein model in the CpOGA-GlcNAcstatin C complex (PDB entry
2J62) (Dorfmueller et al. [2006]), and completed by iterative model building
using COOT (Emsley and Cowtan, 2004) and refinement with REFMAC (Mur-
shudov et al., 1997) (Final R, Rfree at 2.5 A˚ resolution: 0.197, 0.236).
Inhibitor Potency and Mode of Action
Steady-state kinetics (measurements were performed in triplicate) and inhibi-
tion constants (Ki) for GlcNAcstatin derivatives were determined using the
fluorogenic assay as described previously (Dorfmueller et al., 2009).
The mode of inhibition was visually verified by a Lineweaver-Burk plot
(Figure 1B) and the Ki determined by fitting all fluorescence intensity data to
the standard equation for competitive inhibition in GraFit (Leatherbarrow,
2001) (Table 1). IC50 measurements with hHexA/B (Sigma A6152) activitiesChemistry & Biology 17, 1250–125against GlcNAcstatins F, G, and H were performed using the fluorogenic
4MU-NAG substrate and standard reaction mixtures as described previously
(Dorfmueller et al., 2009) (Figure 1C).
Cell-Based Assays and Western Blots
For the O-GlcNAc western blots, HEK293 cells were cultured and treated with
GlcNAcstatin derivatives as described previously (Dorfmueller et al., 2009).
Cell lysates were separated by SDS PAGE, and O-GlcNAcylation was
detected by western blotting with the anti-O-GlcNAc CTD110.6 antibody
and quantified (Dorfmueller et al., 2009). To calculate the EC50 values of
GlcNAcstatins C, F, and G, the data, background corrected with the untreated
cells, were plotted against the inhibitor concentrations using the program
GraphPad Prism (http://www.graphpad.com).
For the microscopy studies, HEK293 cells were seeded in clear flat-bottom
96well assay plates (Corning 3340) and grown for 12 hr at 37C under 5%CO2.
Cells were treated with concentrations of GlcNAcstatins G and H (1% final
DMSO concentration) for 6 hr. Cells were washed twice with 50 ml PBS and
fixed in 3.7% formaldehyde for 10 min at 37C. After washing with TBST
(0.1% Triton X-100) and permeabilized for further 10 min, the cells were
blocked with 2% BSA and 0.1% normal donkey serum in TBST for 1 hr at
RT, followed by washing twice with TBST. Cells were immunostained with
the RL2O-GlcNAc antibody (1/500) for 12 hr at 4C and fluorescent secondary
(1/500) for 1 hr at RT. Cells were further washed twice with TBS before incuba-
tion with DAPI (5 mg/ml) and CellMask (1/25000). Cells were washed twice with
TBS and stored in 50 ml PBS. Images were taken and analyzed with the IN Cell
Analyzer 1000 system (GE Healthcare).
Determination of Intracellular GlcNAcstatin G Concentration
HEK293 cells were treated as described above with two concentrations (1 and
10 mM) of GlcNAcstatin G for 1.5 and 6 hr. Cells were washed twice in ice-cold
PBS and harvested in lysis buffer. The soluble fraction was separated from cell
debris by centrifugation and direct analysis performed by UPLC-MS/MS on
a Quattro Premier XE mass spectrometer using positive electrospray ionization
(Waters, UK) in multiple reaction-monitoring mode. A calibration curve was con-
structed in lysis buffer to cover approximately 3 orders ofmagnitude for GlcNAc-
statinG (i.e., 0.25–500nM). Tocalculate theminimal intracellular concentration of
GlcNAcstatin G, the number and average size (diameter in mm) of cultured
HEK293 cells that were used in this study were analyzed using a Cellometer
Auto T4 from Nexcelom Bioscience. Subsequently, the maximal intracellular
volume was approximated as V = (4/3) 3 p 3 r3, assuming a spherical cell and
ignoring effects of intracellular compartments and proteins. To calculate the total
maximal volume of the intracellular volume in a 2 ml culture, the total number of
HEK293 cells was calculated and multiplied by the average single-cell volume.
This volume was used to determine theminimal dilution factor of the intracellular
volume upon cell lysis. To determine the cellular uptake and, thus, the minimal
concentration of freely available GlcNAcstatin G, the concentration of the
compound determined byUPLC-MS/MSwas corrected using the dilution factor.5, November 24, 2010 ª2010 Elsevier Ltd All rights reserved 1253
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Figure 3. hOGA Inhibitors GlcNAcstatins G and H Elevate O-GlcNAc Levels in HEK293 Cells
(A) HEK293 cells were incubated with GlcNAcstatins C, F, and G for 6 hr at a range of doses. CellularO-GlcNAcylation levels were qualitatively analyzed using an
O-GlcNAc antibody. Densitometric quantitation of single western blots (GlcNAcstatins C and F) and of three O-GlcNAc western blots (GlcNAcstatin G) reveals
EC50 values of 20 nM for GlcNAcstatin C, 290 nM for GlcNAcstatin F, and 20 nM for GlcNAcstatin G.
(B) Immunostaining using an O-GlcNAc antibody shows an elevation of total O-GlcNAc modification (green) of HEK293 cells. Increased concentrations of
GlcNAcstatins G and H induce hyper-O-GlcNAcylation. Dose-response curves of GlcNAcstatin treatments demonstrate the efficiency of the inhibition. Images
were analyzed with the IN cell analyzer, and O-GlcNAc signal in each frame was normalized over the DAPI signal (blue). The scale bar represents 20 mm.
See also Figure S1.
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Table 2. Details of Data Collection and Structure Refinement for
GlcNAcstatin F Bound to V331C-CpOGA
V331C-CpOGA-GlcNAcstatin F
Unit cell (A˚) a = 130.2
b = 145.0
c = 153.1
Resolution range (A˚) 20.0–2.4 (2.5–2.4)
Number of observed reflections 214,504
Number of unique reflections 53,607 (4,916)
Redundancy 4.0 (3.6)
I/sI 14.7 (2.3)
Completeness (%) 95.9 (88.6)
Rmerge 0.129 (0.606)
Number of protein residues 1,170
Number of water molecules 454
R, Rfree 0.197, 0.235
RMSD from ideal geometry
—Bonds (A˚) 0.01
—Angles () 1.3
B-factor RMSD (A˚2)
— (backbone bonds) 31.6
<B > (A˚2)
—Protein 31.6
—Inhibitor 32.1
—Solvent 32.9
Values in parentheses are for the highest resolution shell. All measured
data were included in structure refinement. The space group was I212121.
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